Re: Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.

Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.

Is it safe to omit baseline bone scan for newly diagnosed prostate cancer patients?

When to perform bone scintigraphy in patients with newly diagnosed prostate cancer? a retrospective study.

Natural history of untreated prostate specific antigen radiorecurrent prostate cancer in men with favorable prognostic indicators.

Assessment of value of routine bone scans in patients with newly diagnosed prostate cancer.

Computer-assisted interpretation of planar whole-body bone scintigraphy in patients with newly diagnosed prostate cancer.

Prospective multicenter study of bone scintigraphy in consecutive patients with newly diagnosed prostate cancer.

$Re: Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer.$
Re: Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer.

ml.

CT-Positive Paget Disease in a Patient with Newly Diagnosed Prostate Cancer: Imaging and Bone Biopsy Findings.

Prostate-specific antigen testing in untreated and treated prostatic adenocarcinoma.

Prostate-specific antigen and other serum and urine markers in prostate cancer.

Predictors of survival in prostate cancer patients with bone metastasis and extremely high prostate-specific antigen levels.

Re: Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.

Developing a decision aid to support informed choices for newly diagnosed patients with localized prostate cancer.

Development of a nomogram model predicting current bone scan positivity in patients treated with androgen-deprivation therapy for prostate cancer.

The PXR rs7643645 polymorphism is associated with the risk of higher prostate-specific antigen levels in prostate cancer patients.

Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer.

Super bone scan: bone metastases of prostate cancer.

Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level.

Parameters predicting for prostate specific antigen response rates at one year post low-dose-rate intraoperative prostate brachytherapy.

Factors associated with emotional distress in newly diagnosed prostate cancer patients.

Prostate cancer detection rate in patients with fluctuating prostate-specific antigen levels on the repeat prostate biopsy.

Prostate-specific membrane antigen-based imaging in prostate cancer: impact on clinical decision making process.

Suggest Documents

Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.

Is it safe to omit baseline bone scan for newly diagnosed prostate cancer patients?

When to perform bone scintigraphy in patients with newly diagnosed prostate cancer? a retrospective study.

Natural history of untreated prostate specific antigen radiorecurrent prostate cancer in men with favorable prognostic indicators.

Assessment of value of routine bone scans in patients with newly diagnosed prostate cancer.

Computer-assisted interpretation of planar whole-body bone scintigraphy in patients with newly diagnosed prostate cancer.

Prospective multicenter study of bone scintigraphy in consecutive patients with newly diagnosed prostate cancer.

Re: Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer.

ml.

CT-Positive Paget Disease in a Patient with Newly Diagnosed Prostate Cancer: Imaging and Bone Biopsy Findings.

Prostate-specific antigen testing in untreated and treated prostatic adenocarcinoma.

Prostate-specific antigen and other serum and urine markers in prostate cancer.

Predictors of survival in prostate cancer patients with bone metastasis and extremely high prostate-specific antigen levels.

Re: Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.

Developing a decision aid to support informed choices for newly diagnosed patients with localized prostate cancer.

Development of a nomogram model predicting current bone scan positivity in patients treated with androgen-deprivation therapy for prostate cancer.

The PXR rs7643645 polymorphism is associated with the risk of higher prostate-specific antigen levels in prostate cancer patients.

Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer.

Super bone scan: bone metastases of prostate cancer.

Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level.

Parameters predicting for prostate specific antigen response rates at one year post low-dose-rate intraoperative prostate brachytherapy.

Factors associated with emotional distress in newly diagnosed prostate cancer patients.

Prostate cancer detection rate in patients with fluctuating prostate-specific antigen levels on the repeat prostate biopsy.

Prostate-specific membrane antigen-based imaging in prostate cancer: impact on clinical decision making process.

Re: Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.

Recommend Documents

Follow Us